MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
ET
- ET
LONDON and NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive clinical data from the completed Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia (RIX). - “Today we are releasing data from the completed Phase 1 AQUAx study which now includes the final 12 month data from all bilaterally treated participants.
- AQUAx is an open label, multi-center, dose escalation study of a single administration of AAV2-hAQP1 to one or both parotid glands in participants with radiation-induced salivary hypofunction and grade 2/3 xerostomia.
- All participants were followed for 1-year post-treatment in the Phase 1 AQUAx study and were then enrolled in a long-term follow-up study for a total of 5 years.